Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Analysts Presentations, Conference Calls In Brief

Executive Summary

Bayer's vardenafil is Nuviva: Bayer's brand name for vardenafil is Nuviva, R&D Board Committee Chair Frank Morich, PhD, announced during a press briefing March 13. An NDA for the erectile dysfunction drug is pending at FDA; Bayer expects approval in the second half of 2002. Nuviva will be co-promoted with GlaxoSmithKline...

You may also be interested in...



Bayer/GSK vardenafil 

Trade name for erectile dysfunction disorder drug vardenafil is Levitra, Bayer and GlaxoSmithKline announce. Bayer had earlier referred to the drug as Nuviva; the name was one of several submitted to FDA for approval (1"The Pink Sheet" March 18, p. 29). The companies received an "approvable" letter for vardenafil in July; approval is expected in 2003 (2"The Pink Sheet" July 29, In Brief)...

Bayer/GSK vardenafil 

Trade name for erectile dysfunction disorder drug vardenafil is Levitra, Bayer and GlaxoSmithKline announce. Bayer had earlier referred to the drug as Nuviva; the name was one of several submitted to FDA for approval (1"The Pink Sheet" March 18, p. 29). The companies received an "approvable" letter for vardenafil in July; approval is expected in 2003 (2"The Pink Sheet" July 29, In Brief)...

Bayer Pharma Partnership Announcement Expected By Year-End

Bayer expects to announce a partnership for its pharmaceutical business by the end of the year, Board Chairman Werner Wenning told analysts during a discussion of first half results Aug. 1

UsernamePublicRestriction

Register

PS039464

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel